XFOR

Company Overview — What Does X4 Pharmaceuticals, Inc Do?

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals, Inc (XFOR) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Paula S. Ragan and employs approximately 80 people. With a market capitalization of $396M, XFOR is one of the notable companies in the Healthcare sector.

X4 Pharmaceuticals, Inc (XFOR) Stock Rating — Reduce (April 2026)

As of April 2026, X4 Pharmaceuticals, Inc receives a Reduce rating with a composite score of 29.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.XFOR ranks #2,251 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, X4 Pharmaceuticals, Inc ranks #261 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

XFOR Stock Price and 52-Week Range

X4 Pharmaceuticals, Inc (XFOR) currently trades at $4.10. The stock gained $0.03 (0.7%) in the most recent trading session. The 52-week high for XFOR is $6.63, which means the stock is currently trading -38.2% from its annual peak. The 52-week low is $0.17, putting the stock 2310.4% above its annual trough. Recent trading volume was 235K shares, suggesting relatively thin trading activity.

Is XFOR Overvalued or Undervalued? — Valuation Analysis

X4 Pharmaceuticals, Inc (XFOR) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.50x, versus the sector average of 2.75x. The price-to-sales ratio is 71.10x, compared to 1.66x for the average Healthcare stock.

At current multiples, X4 Pharmaceuticals, Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

X4 Pharmaceuticals, Inc Profitability — ROE, Margins, and Quality Score

X4 Pharmaceuticals, Inc (XFOR) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -149.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -56.2% versus the sector average of -33.1%.

On a margin basis, X4 Pharmaceuticals, Inc reports gross margins of -51.4%, compared to 71.5% for the sector. The operating margin is -2617.7% (sector: -66.1%). Net profit margin stands at -2475.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 178.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

XFOR Debt, Balance Sheet, and Financial Health

X4 Pharmaceuticals, Inc has a debt-to-equity ratio of 122.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 5.65x, indicating strong short-term liquidity. Total debt on the balance sheet is $75M. Cash and equivalents stand at $70M.

XFOR has a beta of 1.18, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for X4 Pharmaceuticals, Inc is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

X4 Pharmaceuticals, Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, X4 Pharmaceuticals, Inc reported revenue of $5M and earnings per share (EPS) of $-0.69. Net income for the quarter was $-92M. Gross margin was -51.4%. Operating income came in at $-98M.

In Q3 2025, X4 Pharmaceuticals, Inc reported revenue of $2M and earnings per share (EPS) of $-0.69. Net income for the quarter was $-30M. Gross margin was 77.6%. Revenue grew 179.6% year-over-year compared to Q3 2024. Operating income came in at $-28M.

In Q2 2025, X4 Pharmaceuticals, Inc reported revenue of $2M and earnings per share (EPS) of $-3.47. Net income for the quarter was $-26M. Gross margin was 81.3%. Revenue grew 209.8% year-over-year compared to Q2 2024. Operating income came in at $-26M.

In Q1 2025, X4 Pharmaceuticals, Inc reported revenue of $900,000 and earnings per share (EPS) of $0.04. Net income for the quarter was $282,000. Gross margin was -424.0%. Operating income came in at $-9M.

Over the past 8 quarters, X4 Pharmaceuticals, Inc has demonstrated a growth trajectory, with revenue expanding from $0 to $5M. Investors analyzing XFOR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

XFOR Dividend Yield and Income Analysis

X4 Pharmaceuticals, Inc (XFOR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

XFOR Momentum and Technical Analysis Profile

X4 Pharmaceuticals, Inc (XFOR) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

XFOR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, X4 Pharmaceuticals, Inc (XFOR) ranks #261 out of 838 stocks based on the Blank Capital composite score. This places XFOR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing XFOR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full XFOR vs S&P 500 (SPY) comparison to assess how X4 Pharmaceuticals, Inc stacks up against the broader market across all factor dimensions.

XFOR Next Earnings Date

No upcoming earnings date has been announced for X4 Pharmaceuticals, Inc (XFOR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy XFOR? — Investment Thesis Summary

The quantitative profile for X4 Pharmaceuticals, Inc suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 13/100) increases portfolio risk.

In summary, X4 Pharmaceuticals, Inc (XFOR) earns a Reduce rating with a composite score of 29.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on XFOR stock.

Related Resources for XFOR Investors

Explore more research and tools: XFOR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare XFOR head-to-head with peers: XFOR vs AZN, XFOR vs SLGL, XFOR vs VMD.